This trial is evaluating whether AMG 160 will improve 6 primary outcomes and 12 secondary outcomes in patients with Carcinoma, Non-Small-Cell Lung. Measurement will happen over the course of Up to 24 weeks.
This trial requires 50 total participants across 3 different treatment groups
This trial involves 3 different treatments. AMG 160 is the primary treatment being studied. Participants will be divided into 3 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
Lung cancer was associated with exposure to asbestos, tobacco smoking, family smoking history and environmental tobacco smoke. Although there is no clear evidence, it is believed that asbestos plays an essential role in the pathogenesis of lung cancer.
Common treatments for carcinoma, non-small-cell lung involve surgery, chemotherapy, radiotherapy, and targeted therapy. There has not been an accurate identification of optimal treatment for [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer). In addition, the number of cancers diagnosed and the percentage of cases with metastases at the time of diagnosis in a given group of patients differ from group to group. Thus, a decision for treatment should be taken with consideration of the patients' age, overall clinical status, disease stage, and underlying pathology in each individual case.
There is no evidence to suggest that carcinoma, non-small-cell lung is a curable disease. However, it is unlikely for lung carcinoma to be recurrent at the time of disease recurrence. Therefore, lung carcinoma cases with high TNM involvement grades should be considered for adjuvant treatment for recurrence at a later stage.
Most of the lesions involved with carcinoma of the lung were detected on CT. Most of the lesions of carcinoma, non-small-cell lung did not involve the upper lobes. There was a higher percentage of consolidation in the lower lung fields, whereas pleural thickening and a halo sign were more frequently seen in the upper lobes. Thus, carcinoma, nontnepositive for cancer may present as an advanced carcinoma with a halo sign on CT.
Approximately 3.8 million American adults are diagnosed with lung carcinoma each year. This makes up 4.1% of all adult neoplasms. Patients must be informed of the possibility of long-term cancer risk if lung carcinoma in situ is found at first bronchoscopy.
Lung cancer is the third-leading cause of cancer-related death in women and second-leading cause or major cause of death for both women and men in the United States. The United States National Conference of Chief Medical Oncologists (NCOCM) published initial clinical guidelines for the diagnosis, treatment, and follow-up of patients with non-small-cell lung cancer in December, 2007. As such, this report is dedicated to the memory of Dr. Harold F. Fletcher, the late dean and CEO of the University of Pennsylvania School of Medicine and a leader in lung cancer treatment and research.
The cause of cancer, non-small-cell lung is thought to originate in the bronchus and other branching parts of respiratory tract; therefore, lung cancer is the most common cancer in the lung. However, some studies showed different results. For example, some studies showed that tobacco was not the main cause of cancer, non-small-cell lung and others showed no relationship with cancer, as a causative factor of both lung cancer and lung cancer, non-small-cell lung. Therefore, it is necessary to investigate more precise causes of lung cancer, besides smokers. Although, smoking seems to be a risk factor in lung cancer, there is a need for more precise studies.
We are still interested, as amg 160 in combination with dacarbazine is safe and effective in treating patients with advanced colorectal cancer. This phase II study provides further evidence to show that amg 160, given in a dose of 120 mg subcutaneously every 3 days in combination with dacarbazine 350 mg subcutaneously every 6 days, is safe and has activity in this disease. A similar trial using amg 160 combined with melphalan is currently ongoing. In addition, this compound has been tested as a possible treatment modality for patients with advanced NSCLC who are not eligible for traditional therapy based on EGFR mutations.
Amg 160 was generally well tolerated. Mild to moderate hepatic adverse events occurred in 3% of placebo and 5% of Amg 160 treatment sessions, in most cases reversible with treatment discontinuation (> or =6%) and not related to amg 161 content or dosage. There were no fatalities associated with Amg 160 in healthy subjects during an extensive safety evaluation. Overall mortality in cancer patients is about 2%, therefore, amg 160 would qualify as a probable carcinogen. An excess risk for malignancies and cancers of the liver might be expected to occur in patients concurrently receiving amg 160 with chemotherapy, but data to support this assumption do not yet exist.
The risk of developing non-small-cell [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer) is 3.6% per year among women and 1.8% per year among men (relative risk: 0.38). These estimates are comparable to the odds given in some recent lung cancer risk tables. Cancer of the pancreas is also a rare cancer among males (relative risk: 0.05) and very rare in females. These risks of developing lung cancer for men and for women must be taken into account when deciding whether to do a screening program for lung cancer.
In patients with unresectable or recurrent carcinoma, amg 160 did not improve quality of life, compared with placebo. Results from a recent clinical trial support the recommendation of FDA for amg 160 to be approved for the treatment of non-small cell lung carcinoma.